213 related articles for article (PubMed ID: 27189287)
1. Efficacy and Safety of Roflumilast in Korean Patients with COPD.
Lee JS; Hong YK; Park TS; Lee SW; Oh YM; Lee SD
Yonsei Med J; 2016 Jul; 57(4):928-35. PubMed ID: 27189287
[TBL] [Abstract][Full Text] [Related]
2. Roflumilast in Asian patients with COPD: A randomized placebo-controlled trial.
Lee SD; Hui DS; Mahayiddin AA; Roa CC; Kwa KH; Goehring UM; Bredenbröker D; Kuo HP
Respirology; 2011 Nov; 16(8):1249-57. PubMed ID: 21848706
[TBL] [Abstract][Full Text] [Related]
3. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
[TBL] [Abstract][Full Text] [Related]
4. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.
Calverley PM; Martinez FJ; Fabbri LM; Goehring UM; Rabe KF
Int J Chron Obstruct Pulmon Dis; 2012; 7():375-82. PubMed ID: 22791991
[TBL] [Abstract][Full Text] [Related]
5. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
Calverley PM; Rabe KF; Goehring UM; Kristiansen S; Fabbri LM; Martinez FJ;
Lancet; 2009 Aug; 374(9691):685-94. PubMed ID: 19716960
[TBL] [Abstract][Full Text] [Related]
6. Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study.
Zheng J; Yang J; Zhou X; Zhao L; Hui F; Wang H; Bai C; Chen P; Li H; Kang J; Brose M; Richard F; Goehring UM; Zhong N
Chest; 2014 Jan; 145(1):44-52. PubMed ID: 24135893
[TBL] [Abstract][Full Text] [Related]
7. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
Rennard SI; Calverley PM; Goehring UM; Bredenbröker D; Martinez FJ
Respir Res; 2011 Jan; 12(1):18. PubMed ID: 21272339
[TBL] [Abstract][Full Text] [Related]
8. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Pinner NA; Hamilton LA; Hughes A
Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994
[TBL] [Abstract][Full Text] [Related]
9. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
Fabbri LM; Calverley PM; Izquierdo-Alonso JL; Bundschuh DS; Brose M; Martinez FJ; Rabe KF;
Lancet; 2009 Aug; 374(9691):695-703. PubMed ID: 19716961
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of roflumilast in the COPD frequent exacerbator phenotype.
Wedzicha JA; Rabe KF; Martinez FJ; Bredenbröker D; Brose M; Goehring UM; Calverley PMA
Chest; 2013 May; 143(5):1302-1311. PubMed ID: 23117188
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis.
Yan JH; Gu WJ; Pan L
Pulm Pharmacol Ther; 2014 Feb; 27(1):83-9. PubMed ID: 23624309
[TBL] [Abstract][Full Text] [Related]
12. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
Rutten-van Mölken MP; van Nooten FE; Lindemann M; Caeser M; Calverley PM
Pharmacoeconomics; 2007; 25(8):695-711. PubMed ID: 17640111
[TBL] [Abstract][Full Text] [Related]
13. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.
Giembycz MA; Field SK
Drug Des Devel Ther; 2010 Jul; 4():147-58. PubMed ID: 20689641
[TBL] [Abstract][Full Text] [Related]
14. Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis.
Yuan L; Dai X; Yang M; Cai Q; Shao N
Int J Chron Obstruct Pulmon Dis; 2016; 11():1477-83. PubMed ID: 27418821
[TBL] [Abstract][Full Text] [Related]
15. Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials.
Rennard SI; Sun SX; Tourkodimitris S; Rowe P; Goehring UM; Bredenbröker D; Calverley PM
Int J Chron Obstruct Pulmon Dis; 2014; 9():657-73. PubMed ID: 25018629
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.
Janjua S; Fortescue R; Poole P
Cochrane Database Syst Rev; 2020 May; 5(5):CD002309. PubMed ID: 32356609
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Oba Y; Lone NA
Ther Adv Respir Dis; 2013 Feb; 7(1):13-24. PubMed ID: 23197074
[TBL] [Abstract][Full Text] [Related]
18. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD.
Grootendorst DC; Gauw SA; Verhoosel RM; Sterk PJ; Hospers JJ; Bredenbröker D; Bethke TD; Hiemstra PS; Rabe KF
Thorax; 2007 Dec; 62(12):1081-7. PubMed ID: 17573446
[TBL] [Abstract][Full Text] [Related]
19. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
20. A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease.
Wells JM; Jackson PL; Viera L; Bhatt SP; Gautney J; Handley G; King RW; Xu X; Gaggar A; Bailey WC; Dransfield MT; Blalock JE
Am J Respir Crit Care Med; 2015 Oct; 192(8):934-42. PubMed ID: 26151090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
